Serum suPAR concentrations in patients with focal segmental glomerulosclerosis with end-stage renal disease

Kidney International

Volumn 85, Issue 3, 2014, Pages 711-

  Maas, Rutger J H ^a   Wetzels, Jack F M ^a   Deegens, Jeroen K J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE RECEPTOR; SOLUBLE UROKINASE RECEPTOR; UNCLASSIFIED DRUG;

DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TRANSPLANTATION; LETTER; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RECURRENCE RISK; RECURRENT DISEASE; BLOOD; FEMALE; MALE; CHRONIC KIDNEY DISEASE; HEMODIALYSIS; KIDNEY ALLOGRAFT; PROTEINURIA;

FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MALE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 84895153177     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.513     Document Type: Letter

References (4)

1. Huang J, Liu G, Zhang YM et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 2013; 84: 366-372.
2. Wei C, Trachtman H, Li J et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012; 23: 2051-2059.
3. Wei C, El Hindi S, Li J et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17: 952-960.
4. Franco Palacios CR, Lieske JC, Wadei HM et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 2013; 96: 394-399.